Applied Therapeutics Inc (APLT)

Applied Therapeutics completes merger with Cycle Group Holdings, delists from Nasdaq (2/03/26)

https://www.sec.gov/Archives/edgar/data/1697532/000119312526034559/d93556d8k.htm

APLT...................................https://stockcharts.com/sc3/ui/?s=APLT&p=W&b=5&g=0&id=p86431144783

Getting good traffic today with a volume spike.
.50 near term imho.

.29.  Regulatory UpdateAs previously announced, the Company completed a Type C meeting with the United States Food and Drug Administration (FDA) regarding govorestat for the treatment of Charcot-Marie-Tooth Sorbitol Dehydrogenase (SORD) Deficiency (CMT-SORD) in the third quarter of 2025. The Company is evaluating the official Type C meeting minutes and post-meeting written correspondence and expects to submit a request for an additional Type C meeting with the FDA with the intent of further discussing a potential Phase 3 trial design.Additionally, the Company recently accepted written feedback from the FDA in connection with its planned meeting on the body of govorestat data submitted by the Company for Classic Galactosemia. The Company is evaluating the feedback with its advisors as it assesses next steps for the development of govorestat for the treatment of Classic Galactosemia. The Company may pursue additional discussions with the FDA regarding a potential Phase 3 trial design at a later date.About Applied TherapeuticsApplied Therapeutics is a clinical-stage bioph

.28 Get in when in .20s get out when in .30s -.40s let's play this game again

It will move a lot more. And soon.

It did move

aplt watch for a big move maybe.

APLT....................................................https://stockcharts.com/sc3/ui/?s=APLT&p=W&b=5&g=0&id=p86431144783

.30 Good Friday too Monday flipper on the pullback

A steal at .22 Friday at .31 now 

.27 nice entry zome m for flips

Back in with 10k at.345.

I love the smell of char-broiled shorts in the ofternoon.😄

3 bagger so far.
This baby is headed for $3. 
I'll take that ten-bagger.😀

APLT...................................................https://stockcharts.com/h-sc/ui?s=APLT&p=W&b=5&g=0&id=p86431144783

Grabar Law Office Investigates Claims on Behalf of Shareholders of Applied Therapeutics, Inc. (APLT) As Securities Fraud Class Action Reaches Settlement

Philadelphia, Pennsylvania--(Newsfile Corp. - September 9, 2025) - Grabar Law Office is investigating claims on behalf of shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Applied Therapeutics (NASDAQ: APLT) shares prior to January 3, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/applied-therapeutics-shareholder-investigation/, contact Joshua Grabar at jgrabar @FH-6085 to learn more.

WHY? As alleged in a recently filed securities fraud class action complaint, Applied Therapeutics, Inc. (NASDAQ: APLT), through certain of its officers, provided positive statements to investors while, at the same time, disseminating false and materially misleading statements and/or concealing material adverse facts concerning the true state of Applied Therapeutics' Phase III INSPIRE trial; notably, electronic data capture issues and a dosing error in the dose-escalation phase of the study. The Complaint further alleges that such statements absent these material facts caused Plaintiff and other shareholders to purchase Applied Therapeutics' securities at artificially inflated prices.

On August 25, 2025, the parties reported to the Court that they had agreed to settle the securities fraud class action.

WHAT YOU CAN DO NOW:If you purchased Applied Therapeutics (NASDAQ: APLT) shares prior to January 3, 2024, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/applied-therapeutics-shareholder-investigation/, contact Joshua Grabar at jgrabar @FH-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.

$APLT #AppliedTherapeutics

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com

Got a double now, so I sold 25%
Will sell the rest at $1.50 for a five bagger with the rest.
Chers!

APLT......................................https://stockcharts.com/h-sc/ui?s=APLT&p=W&b=5&g=0&id=p86431144783

Poor shorts are starting to get rather nervous.
But this is only the beginning. See you above $1 soon!😁

Oops.....starting to move up a little more, shall we say, vigorously
😁

Shorts Will provide the rocket fuel when they begin covering, as usual.
😃

In with a boatload and at an average of .312.
Double any day from here.
Tick tock......

Gotcha…

Better opportunity elsewhere

Are you in too TT? Shhh….

Happy Saturday Monk! Would you be long a thus point? .55?

Get in for a DOUBLE+!

It will happen as soon as they present their data to the FDA during this quarter (any day now).

YES

DESPERATE manipulation going on courtesy of the ambulance chasers. 

Double coming soon - maybe much more. LOL

$APLT$

APLT.................................https://stockcharts.com/h-sc/ui?s=APLT&p=W&b=5&g=0&id=p86431144783

Easy DOUBLE coming up here soon.

$APLT$

YES

APLT..............................................https://stockcharts.com/h-sc/ui?s=APLT&p=W&b=5&g=0&id=p86431144783

Added 3000 today at .5407.

$APLT$

And what will happen with all the frivolous lawsuits?

When the price triples in one day from here, the stock will continue to recover, moving higher and higher until the lawsuits, along with our ambulance chaser friends will look like bafoons.

YES

$APLT$

APLT's strategy is to present to the FDA  in Q1 of 2025 their results Galactosemia, SORD Deficiency, and PMM2-CDG. The company is also developing AT-001 for Diabetic Cardiomyopathy and Diabetic Peripheral Neuropathy, and AT-003 for Diabetic Retinopathy, addressing significant unmet needs in diabetes care.


If ANY of these results have ANY success, we are looking at a four bagger in a single day from these levels.


The risk/reward is highly attractive.

Short covering has officially begun. 😁

It's up from here. Maybe a few shenanigans are still in store, but it's up from here.

Would not be surprised to see a double suddenly on a volume spike. Just look at the time and sales from last Friday.

About 5 million shares were bought in the last 5 minutes of trading. Somebody knows something.

Was this the bottom?

Jumped in with a starter at .64

Any halfway decent news will spike this IMHO.

The company has been totally "crickets" since the debacle of some weeks ago.

But truth be told, a decent PR from theses folks could send this spiking to the upside.

All you need is a few cojones. lol😅

APLT...................https://stockcharts.com/h-sc/ui?s=APLT&p=W&b=5&g=0&id=p86431144783

aplt.............................................https://stockcharts.com/h-sc/ui?&s=aplt&id=p80904663129&listNum=4&a=1431976465

What is the Lawsuit About?

Applied Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel drug candidates against validated molecular targets in rare diseases. The Company's lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases, including Galactosemia.

During the relevant period, the Company stated that its New Drug Applications submitted to regulators for govorestat were“supported by rapid and sustained reduction in galactitol, which resulted in a meaningful benefit on clinical outcomes across pediatric patients, alongside a favorable safety profile.” Applied Therapeutics also assured investors that its tests were“performed properly” and that the Company“felt good about the quality of the data,” stating that it“took really extensive steps” and“actually videotaped” and had“master trainers” review all of the performances of the 10-meter walk-run test-the primary endpoint of the Company's Phase III INSPIRE study for govorestat.

The Stock Declines as the Truth is Revealed
On November 27, 2024, Applied Therapeutics issued a press release stating that the FDA issued a Complete Response Letter for the NDA for govorestat. The Complete Response Letter stated that the FDA completed its review of the application and determined that it was unable to approve the NDA due to“deficiencies in the clinical application.”

This news caused the price of Applied Therapeutics stock to fall more than 80% over the course of multiple trading days, from a closing price of $10.21 per share on November 26, 2024 to a closing price of $1.75 per share on December 2, 2024.

Then, on December 2, 2024, Applied Therapeutics revealed that it received a warning letter from the FDA relating to its govorestat study discussing“issues related to electronic data capture” and“a dosing error in the dose-escalation phase of the study resulting in slightly lower levels than targeted in a limited number of patients[.]”

This news caused the price of Applied Therapeutics stock to fall more than 26% over the course of multiple trading days, from a closing price of $1.75 per share on December 2, 2024 to a closing price of $1.29 per share on December 5, 2024.

Click here for more information: .

What Can You Do?

If you invested in Applied Therapeutics you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


Or contact:
Ross Shikowitz
...
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit .


Attorney advertising. Past results do not guarantee future outcomes.




MENAFN01012025004107003653ID1109046768


GlobeNewsWire - Nasdaq
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.


Tags

Label
Comments

No comment
Category


Date

1/1/2025

Most popular stories
Poland Assumes EU Council Presidency With Focus On Security...
Poland Assumes EU Council Presidency With Focus On Security...
When Will Rigetti And These Two Stock Rally End?...
When Will Rigetti And These Two Stock Rally End?...
Dubai: Is It Time To Shift From Gold To Diamonds? Changing Jewellery T...
Dubai: Is It Time To Shift From Gold To Diamonds? Changing Jewellery T...
Dubai: Gold Prices Jump In Early Trade On New Year, Set To Stay High I...
Dubai: Gold Prices Jump In Early Trade On New Year, Set To Stay High I...
'Bruce Lee Of Afghanistan' Dreams Visting Hong Kong, Performing In Mov...
'Bruce Lee Of Afghanistan' Dreams Visting Hong Kong, Performing In Mov...
M&M 11Th Most Valuable Automobile Manufacturer In World: Anand Mahindr...
M&M 11Th Most Valuable Automobile Manufacturer In World: Anand Mahindr...

Market Research
Market Research

Manuka Honey Market Report 2024, Industry Growth, Size, Share, Top Compan...
Modular Kitchen Market 2024, Industry Growth, Share, Size, Key Players An...
Acrylamide Production Cost Analysis Report: A Comprehensive Assessment Of...
Fish Sauce Market 2024, Industry Trends, Growth, Demand And Analysis Repo...
Australia Foreign Exchange Market Size, Growth, Industry Demand And Forec...
Cold Pressed Oil Market Trends 2024, Leading Companies Share, Size And Fo...
Pasta Sauce Market 2024, Industry Growth, Share, Size, Key Players Analys...

APLT on the move here.

I see a great opportunity here at these levels. That price drop was quite exaggerated.

Option trade today 1/17/25, $12.50 @1,000

Option trade today 1/17/25, $12.50 @1,000

APLT: 200%-up, for sure today.

Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia

APLT under $7